Literature DB >> 6880589

Spinal analgesia with bupivacaine, mepivacaine and tetracaine.

M Bengtsson, H H Edström, J B Löfström.   

Abstract

Spinal analgesia with bupivacaine, tetracaine and mepivacaine was studied in 103 patients in two studies, one open and one double-blind. Injections were given with the patients sitting and they remained seated for 2 min after the injection. Regardless of the agent used, the mean cephalad spread of analgesia was T6-8 15 min after injection. Mepivacaine 4% (60 mg) in glucose produced analgesia and motor blockade of good quality but of short duration. Bupivacaine 0.5% and 0.75% and tetracaine 1%, all solutions with glucose, produced long-lasting blockades, tetracaine 14 mg having a longer duration of action than 15 mg bupivacaine. When 15 mg of bupivacaine was administered in solutions containing glucose, no difference in sensory blockade was seen, regardless of volume (2 or 3 ml, 0.75% and 0.5%, respectively) injected. 3 ml of bupivacaine 0.75% (22.5 mg) in glucose-free solution produced a very long-lasting blockade with deep motor engagement, particularly suitable for hip surgery of long duration. Bupivacaine 0.75% (3 ml, 22.5 mg) in solution with glucose produced a more marked effect on the blood pressure than the other solutions tested.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6880589     DOI: 10.1111/j.1399-6576.1983.tb01951.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  3 in total

1.  The intrathecal spread of hyperbaric dibucaine in adolescents.

Authors:  Y Hirabayashi; R Shimizu
Journal:  J Anesth       Date:  1993-04       Impact factor: 2.078

Review 2.  Clinical pharmacokinetics of epidural and spinal anaesthesia.

Authors:  A G Burm
Journal:  Clin Pharmacokinet       Date:  1989-05       Impact factor: 6.447

3.  Lidocaine 0.5% spinal anaesthesia: a hypobaric solution for short-stay perirectal surgery.

Authors:  M N Bodily; R L Carpenter; B D Owens
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.